Recent Company News

• 03:22 AM ET Feb 12, 2026
  

  StreetAccount Summary: Hong Kong Stocks reaching new 52-week highs/lows (40 total)

• 06:34 PM ET Feb 10, 2026
  

  Wuxi Biologics (Cayman) reports FY preliminary net income attributable CNY4.91B vs FactSet CNY4.49B [13 est, CNY3.71-5.20B] (HK$40.02, 0.00)

• 10:58 PM ET Jan 18, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 01:03 AM ET Feb 04, 2026
  

  StreetAccount Sector Summary - China Healthcare January Recap

• 10:16 PM ET Feb 02, 2026
  

  Wuxi Biologics and Vertex Pharmaceuticals to jointly develop a trispecific T-cell Engager for treating B-cell mediated autoimmune diseases (HK$37.02, +0.02)

• 09:42 PM ET Jan 28, 2026
  

  Wuxi Biologics (Cayman) and Sinorda Biomedicine announce strategic collaboration for the development and manufacturing of SND006 (HK$38.56, +0.44)

• 01:02 AM ET Jan 16, 2026
  

  Street Takeaways - WuXi XDC Cayman guidance update & proposed BioDlink acquisition (HK$70.15, -2.75)

• 07:08 PM ET Jan 15, 2026
  

  Wuxi Biologics (Cayman) substantial shareholder WuXi Biologics Holdings to sell 150M shares; ceases to be a substantial shareholder (HK$40.02, 0.00)

• 10:20 AM ET Jan 14, 2026
  

  WuXi XDC Cayman offers to acquire BioDlink International at HK$4.0/share (HK$2.50, 0.00)